Tesamorelin Dosing Protocol

Tesamorelin acetate (Egrifta) is a synthetic 44-amino acid polypeptide analogue of human growth hormone-releasing hormone (GHRH) and the only currently FDA-approved GHRH analogue. Developed by Theratechnologies, it was approved by the U.S. FDA in November 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Structurally, tesamorelin is a full-length copy of human GHRH (44 amino acids) with a small chemical modification at one end. This modification makes it harder for the body's enzymes to break it down, giving tesamorelin a longer functional tesamorelin half-life than natural GHRH or shorter analogues like sermorelin — while still triggering the body's natural growth hormone release pattern rather than overriding it.

Tesamorelin has one of the strongest clinical programs in peptide therapeutics, including two large Phase III lipodystrophy trials (LIPO-010, n=412; CTR-1011, n=404) and a landmark Lancet HIV NAFLD study reporting liver-fat and fibrosis-progression benefits in HIV-associated populations.

Beyond labeled use, tesamorelin appears in off-label metabolic and body-composition discussions in regenerative medicine settings. Ongoing research includes metabolic syndrome and cognitive outcomes, but those indications remain investigational and clinician-directed.

Tesamorelin is FDA-approved only for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. All information on this page is educational and research-reference only.

Unlike most peptides that require gradual dose escalation, the tesamorelin dosing protocol starts at full therapeutic dose from day one — no titration or ramp-up needed. The table below shows dosing for each available formulation. If you're using grey-market research vials, the 2 mg daily column is the most commonly referenced protocol.

The table below shows how much bacteriostatic water to add to each common tesamorelin vial size, and what syringe volume you'll need for each dose. Find your vial size in the left column, pick the BAC water volume that gives you a comfortable injection volume, then read across to your target dose. Smaller water volumes mean more concentrated solutions (smaller injections), while larger volumes are easier to measure precisely.

Tesamorelin has the most comprehensive safety database of any GHRH analogue, including Phase III data across more than 800 participants.

Injection-site reactions: Most common adverse events include erythema, pruritus, pain, swelling, and rash. In CTR-1011, any injection-site condition occurred in 50.7% versus 21.4% on placebo; in LIPO-010, 30.0% versus 24.1%.

Fluid retention and joint/muscle effects: Swelling (peripheral edema), joint pain (arthralgia), and muscle aches (myalgia) can occur due to growth hormone-related fluid shifts. In trials, swelling occurred in about 9.9% of tesamorelin users versus 5.8% on placebo, with muscle aches in 3.7-7.7% versus 1.6-2.2% on placebo — mild to moderate in most cases.

Blood sugar effects: Phase III data showed that more tesamorelin users had elevated blood sugar markers (HbA1c ≥6.5%) compared to placebo. The FDA label recommends checking blood sugar levels before starting and periodically during treatment.

Antibody development: Anti-tesamorelin IgG antibodies developed in about half of participants at 26-52 weeks. Available analyses showed similar VAT and IGF-1 efficacy signals across antibody-positive and antibody-negative groups.

IGF-1 elevation: IGF-1 elevation is expected pharmacologically. Persistent high levels (for example sustained >3 SDS contexts) may warrant clinician review, dose adjustment, or discontinuation.

Contraindications: Contraindications include active malignancy, pregnancy, known hypersensitivity (including mannitol), and major hypothalamic-pituitary-axis disruption contexts.

Tesamorelin has one of the strongest clinical evidence bases of any peptide. Two large Phase III tesamorelin clinical trials (816 participants combined) showed it reduced deep belly fat (visceral adipose tissue, or VAT) by 12-20% over 26 weeks — a meaningful reduction that most other peptides cannot match with this level of trial evidence. These results led to FDA approval in November 2010. Importantly, when patients stopped taking tesamorelin, belly fat trended back toward pre-treatment levels, which suggests ongoing use is needed to maintain results. The 12-month liver study was especially notable: tesamorelin reduced liver fat by about 32% versus placebo, and only 10.5% of tesamorelin users showed worsening liver scarring compared to 37.5% on placebo. An ongoing registered study (ClinicalTrials.gov NCT02196831) continues to evaluate these outcomes.

Tesamorelin, sermorelin, and CJC-1295 all target the same receptor (GHRH) but differ in important ways. The biggest differences to look for: tesamorelin is the only one with FDA approval and Phase III trial data showing visceral fat reduction; sermorelin has the longest history of clinical use but was discontinued as a prescription product; and CJC-1295 (DAC) requires the fewest injections (weekly versus daily) but has no comparable trial evidence.

Tesamorelin is differentiated by active FDA status plus robust Phase III efficacy evidence, including validated visceral-fat outcomes.

Sermorelin and CJC-1295 share receptor targeting but differ in half-life, evidence depth, and regulatory history.

For protocol-specific context, compare dosing math and outcomes against Sermorelin and CJC-1295 pages.

See the Sermorelin protocol and CJC-1295 protocol for compound-specific guides.